한글목차

원숭이 돼지 몰 원료의약품(API) 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 30억 5,000만 달러에서 2026년에는 32억 5,000만 달러에 이르고, CAGR 6.6%로 성장할 전망입니다. 지난 몇 년간 성장 요인으로는 살부타몰 API의 생산 능력 제약, 천식 및 COPD 환자 증가, 기존 흡입기 및 정제 의존도, 신흥 시장에서의 의약품 생산 확대, 표준 품질 준수 프로토콜 채택 등을 들 수 있습니다.

원숭이 돼지 몰 원료의약품(API) 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 41억 4,000만 달러에 이르고, CAGR은 6.3%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 API 합성 기술의 발전, 제네릭 및 브랜드 호흡기 의약품의 확대, 첨단 제제 기술에 대한 R&D 투자 증가, 규제 당국의 승인 및 인증 증가, 스마트 제조 및 디지털 모니터링 시스템 통합 등이 있습니다. 예측 기간 동안 주요 동향으로는 호흡기 약물 제제에서 살부타몰 API 수요 증가, 흡입 및 경구 투여 방법의 확대, 고순도 및 품질 기준을 충족하는 API 생산에 대한 관심 증가, 천식 및 COPD 치료제의 연구 개발 증가, 온라인 및 소매 약국 유통 채널의 확대 등이 있습니다.

호흡기 질환의 발생률 증가는 향후 몇 년 동안 살부타몰 원료의약품(API) 시장의 성장을 견인할 것으로 예측됩니다. 호흡기 질환이란 폐와 기도에 영향을 미쳐 호흡곤란과 산소 섭취량 감소를 유발하는 병태를 말합니다. 천식, 만성폐쇄성폐질환(COPD), 폐렴, 기관지염, 각종 폐 감염 등이 이에 해당합니다. 호흡기 질환의 유병률 증가는 주로 대기오염의 악화에 기인합니다. 대기오염으로 인해 유해한 오염물질에 노출되면 기도가 자극을 받아 폐 기능이 손상될 수 있습니다. 살부타몰 API는 기도 근육을 이완시키고 기도를 확장시켜 호흡을 편안하게 하여 호흡기 질환 치료에 도움을 줍니다. 천명음, 호흡곤란 등의 증상을 빠르게 완화하고 호흡 효율과 환자의 삶의 질을 향상시킵니다. 예를 들어, 호주 정부 기관인 호주 통계청(ABS)의 2024년 11월 발표에 따르면, 2023년 천식은 전체 질병 부담의 2.5%, 전체 호흡기 질환 부담의 35%를 차지하며 1-9세 아동 질병 부담의 주요 원인으로 나타났습니다. 따라서 호흡기 질환의 발생률 증가가 살부타몰 유효성분(API) 시장의 성장을 견인하고 있습니다.

살부타몰 원료의약품(API) 시장에서 활동하는 주요 기업들은 환경 규제에 대응하고 지속 가능한 치료 옵션을 제공하기 위해 친환경 흡입기와 같은 혁신적인 약물 제제 개발에 주력하고 있습니다. 친환경 흡입기는 지구 온난화 계수가 낮은 추진제 또는 드라이 파우더 흡입기를 포함한 무추진제 전달 시스템을 채택한 호흡기 장치입니다. 예를 들어, 2023년 11월 영국에 본사를 둔 제약회사 GSK plc는 배출량을 최대 90%까지 줄일 수 있는 차세대 추진제를 채택한 저탄소형 벤틀린 흡입기에 대한 임상 3상 시험을 진행한다고 발표했습니다. 벤틀린은 살부타몰(일명 알부테롤)을 함유한 유명 흡입기 브랜드이며, 기도를 확장하고 천식 및 기타 호흡기 질환에 따른 증상을 완화하는 작용을 합니다. 지속가능성을 위한 노력은 추진제의 환경 부하를 줄이는 데 초점을 맞추고 있지만, 흡입기를 통해 투여되는 살부타몰 원료 자체는 변경되지 않습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Salbutamol active pharmaceutical ingredient (API) is the purified, pharmacologically active compound that delivers the desired therapeutic effect in medicines used to manage respiratory disorders. It serves as the core substance for pharmaceutical manufacturers in the production of finished dosage forms such as tablets, inhalers, and syrups.

The main types of salbutamol active pharmaceutical ingredient (API) include salbutamol sulfate and levalbuterol hydrochloride. Salbutamol sulfate is the sulfate salt form of salbutamol, a rapid-acting bronchodilator that helps relieve asthma and other obstructive airway conditions by relaxing airway smooth muscles. The formulation types include inhalation solutions, tablet formulations, syrup formulations, and others. These products are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used for applications such as asthma, chronic obstructive pulmonary disease (COPD), bronchospasm, and other respiratory conditions, serving end users including pharmaceutical companies, research laboratories, and others.

Tariffs have influenced the salbutamol api market by increasing the cost of imported raw materials and chemical intermediates, affecting segments such as salbutamol sulfate and levalbuterol hydrochloride. Regions like Asia-Pacific, particularly India and China, are most impacted due to their major role in global api manufacturing. This has led to higher production costs and adjustments in sourcing strategies. Positively, tariffs have encouraged local production, improved domestic manufacturing capabilities, and spurred innovation in cost-effective api synthesis methods.

The salbutamol active pharmaceutical ingredient (api) market research report is one of a series of new reports from The Business Research Company that provides salbutamol active pharmaceutical ingredient (api) market statistics, including salbutamol active pharmaceutical ingredient (api) industry global market size, regional shares, competitors with a salbutamol active pharmaceutical ingredient (api) market share, detailed salbutamol active pharmaceutical ingredient (api) market segments, market trends and opportunities, and any further data you may need to thrive in the salbutamol active pharmaceutical ingredient (api) industry. This salbutamol active pharmaceutical ingredient (api) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The salbutamol active pharmaceutical ingredient (api) market size has grown strongly in recent years. It will grow from $3.05 billion in 2025 to $3.25 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to limited manufacturing capabilities for salbutamol api, growing prevalence of asthma and copd, reliance on traditional inhalers and tablets, increasing pharmaceutical production in emerging markets, adoption of standard quality compliance protocols.

The salbutamol active pharmaceutical ingredient (api) market size is expected to see strong growth in the next few years. It will grow to $4.14 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to technological advancements in api synthesis, expansion of generic and branded respiratory drugs, rising investment in r&d for advanced delivery formulations, increasing regulatory approvals and certifications, integration of smart manufacturing and digital monitoring systems. Major trends in the forecast period include rising demand for salbutamol api in respiratory drug formulations, expansion of inhalation and oral delivery methods, growing focus on high-purity and quality-compliant api production, increase in research and development for asthma and copd treatments, rising online and retail pharmacy distribution channels.

The increasing incidence of respiratory diseases is expected to drive the growth of the salbutamol active pharmaceutical ingredient (API) market in the coming years. Respiratory diseases are conditions that affect the lungs and airways, resulting in breathing difficulties and reduced oxygen intake. These conditions include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and various lung infections. The rising prevalence of respiratory diseases is largely attributed to increasing air pollution, which exposes individuals to harmful pollutants that irritate the airways and impair lung function. Salbutamol API supports the treatment of respiratory diseases by relaxing airway muscles and widening the air passages, thereby easing breathing. It provides rapid relief from symptoms such as wheezing and shortness of breath, improving respiratory efficiency and patient quality of life. For instance, in November 2024, according to the Australian Bureau of Statistics, an Australia-based government agency, asthma contributed to 2.5% of the total disease burden and 35% of the burden from all respiratory conditions in 2023, and it was the leading cause of disease burden among children aged 1-9 years. Therefore, the growing incidence of respiratory diseases is driving the growth of the salbutamol active pharmaceutical ingredient (API) market.

Major companies operating in the salbutamol active pharmaceutical ingredient (API) market are increasingly focusing on the development of innovative drug formulations, such as eco-friendly inhalers, to comply with environmental regulations and provide sustainable treatment options. Eco-friendly inhalers are respiratory devices that utilize low-global warming potential propellants or propellant-free delivery systems, including dry powder inhalers. For example, in November 2023, GSK plc, a UK-based pharmaceutical company, announced its progression to Phase III clinical trials for a low-carbon Ventolin inhaler that uses a next-generation propellant capable of reducing emissions by up to 90%. Ventolin is a well-known inhaler brand containing salbutamol, also referred to as albuterol, which works by opening the airways and relieving symptoms associated with asthma and other respiratory disorders. While the sustainability initiative focuses on reducing the environmental impact of the propellant, the salbutamol API delivered through the inhaler remains unchanged.

In April 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, partnered with Launch Therapeutics to accelerate the development of TEV-248, a dual-action asthma rescue inhaler that combines an inhaled corticosteroid (ICS) with a short-acting beta-agonist (SABA). Through this collaboration, Teva and Launch Therapeutics aim to speed up clinical development, enhance patient access, and advance regulatory efforts for this next-generation rescue therapy. In addition, Teva entered into a strategic development funding agreement with Abingworth to further support the program's progression. Launch Therapeutics is a US-based clinical development accelerator specializing in advancing innovative late-stage therapies.

Major companies operating in the salbutamol active pharmaceutical ingredient (api) market are Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Limited, Amphastar Pharmaceuticals Inc., Neuland Laboratories Ltd., Supriya Lifescience Ltd., Lusochimica S.p.A., Intas Pharmaceuticals Ltd., Olon S.p.A., VIVAN Life Sciences, Vamsi Labs Ltd., Aarti Pharmalabs Ltd., Chemcopia, Cerata Pharma, Hetero Labs Ltd., Granules India Ltd., MSN Laboratories Ltd., Macleods Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Ipca Laboratories Ltd., Alembic Pharmaceuticals Ltd., Indoco Remedies Ltd., Jubilant Pharmova Ltd., Laurus Labs Ltd., Teva Active Pharmaceutical Ingredients, Cambrex Corporation, Zhejiang Supor Pharmaceuticals Co. Ltd., Shandong Xinhua Pharmaceutical Co. Ltd., Hubei Gedian Humanwell Pharmaceutical Co. Ltd.

North America was the largest region in the salbutamol active pharmaceutical ingredient (API) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the salbutamol active pharmaceutical ingredient (api) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the salbutamol active pharmaceutical ingredient (api) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The salbutamol active pharmaceutical ingredient (API) market consists of sales of nebulizer solutions, raw salbutamol powder, and injectable salbutamol formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Salbutamol active pharmaceutical ingredient (API) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses salbutamol active pharmaceutical ingredient (api) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for salbutamol active pharmaceutical ingredient (api) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The salbutamol active pharmaceutical ingredient (api) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Salbutamol Sulfate; Levalbuterol Hydrochloride
• 2) By Formulation Type: Inhalation Solutions; Tablet Formulations; Syrup Formulations; Other Delivery Methods
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Asthma; Chronic Obstructive Pulmonary Disease (COPD); Bronchospasm; Other Applications
• 5) By End-User: Pharmaceutical Companies; Research Laboratories; Other End Users
• Subsegments:
• 1) By Salbutamol Sulfate: Inhalation Powder; Inhalation Solution; Oral Tablets; Oral Syrup; Injectable Form
• 2) By Levalbuterol Hydrochloride: Inhalation Solution; Metered Dose Inhaler (MDI); Oral Solution; Nebulizer Solution
• Companies Mentioned: Aurobindo Pharma Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Ltd.; Lupin Limited; Amphastar Pharmaceuticals Inc.; Neuland Laboratories Ltd.; Supriya Lifescience Ltd.; Lusochimica S.p.A.; Intas Pharmaceuticals Ltd.; Olon S.p.A.; VIVAN Life Sciences; Vamsi Labs Ltd.; Aarti Pharmalabs Ltd.; Chemcopia; Cerata Pharma; Hetero Labs Ltd.; Granules India Ltd.; MSN Laboratories Ltd.; Macleods Pharmaceuticals Ltd.; Zydus Lifesciences Ltd.; Glenmark Pharmaceuticals Ltd.; Ipca Laboratories Ltd.; Alembic Pharmaceuticals Ltd.; Indoco Remedies Ltd.; Jubilant Pharmova Ltd.; Laurus Labs Ltd.; Teva Active Pharmaceutical Ingredients; Cambrex Corporation; Zhejiang Supor Pharmaceuticals Co. Ltd.; Shandong Xinhua Pharmaceutical Co. Ltd.; Hubei Gedian Humanwell Pharmaceutical Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Salbutamol Active Pharmaceutical Ingredient (API) Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Salbutamol Active Pharmaceutical Ingredient (API) Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Salbutamol Active Pharmaceutical Ingredient (API) Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Salbutamol Active Pharmaceutical Ingredient (API) Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Industry 4.0 & Intelligent Manufacturing
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Autonomous Systems, Robotics & Smart Mobility
• 4.2. Major Trends
  • 4.2.1 Rising Demand For Salbutamol API In Respiratory Drug Formulations
  • 4.2.2 Expansion Of Inhalation And Oral Delivery Methods
  • 4.2.3 Growing Focus On High-Purity And Quality-Compliant API Production
  • 4.2.4 Increase In Research And Development For Asthma And COPD Treatments
  • 4.2.5 Rising Online And Retail Pharmacy Distribution Channels

5. Salbutamol Active Pharmaceutical Ingredient (API) Market Analysis Of End Use Industries

• 5.1 Pharmaceutical Companies
• 5.2 Research Laboratories
• 5.3 Hospitals And Clinics
• 5.4 Contract Manufacturing Organizations (CMOs)
• 5.5 Diagnostic And Academic Research Institutions

6. Salbutamol Active Pharmaceutical Ingredient (API) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Salbutamol Active Pharmaceutical Ingredient (API) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Salbutamol Active Pharmaceutical Ingredient (API) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Salbutamol Active Pharmaceutical Ingredient (API) Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Salbutamol Active Pharmaceutical Ingredient (API) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Salbutamol Active Pharmaceutical Ingredient (API) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Salbutamol Active Pharmaceutical Ingredient (API) Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Salbutamol Active Pharmaceutical Ingredient (API) Market Segmentation

• 9.1. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Salbutamol Sulfate, Levalbuterol Hydrochloride
• 9.2. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Inhalation Solutions, Tablet Formulations, Syrup Formulations, Other Delivery Methods
• 9.3. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.4. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Asthma, Chronic Obstructive Pulmonary Disease (COPD), Bronchospasm, Other Applications
• 9.5. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pharmaceutical Companies, Research Laboratories, Other End Users
• 9.6. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Sub-Segmentation Of Salbutamol Sulfate, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Inhalation Powder, Inhalation Solution, Oral Tablets, Oral Syrup, Injectable Form
• 9.7. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Sub-Segmentation Of Levalbuterol Hydrochloride, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Inhalation Solution, Metered Dose Inhaler (MDI), Oral Solution, Nebulizer Solution

10. Salbutamol Active Pharmaceutical Ingredient (API) Market Regional And Country Analysis

• 10.1. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Salbutamol Active Pharmaceutical Ingredient (API) Market

• 11.1. Asia-Pacific Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Salbutamol Active Pharmaceutical Ingredient (API) Market

• 12.1. China Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Salbutamol Active Pharmaceutical Ingredient (API) Market

• 13.1. India Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Salbutamol Active Pharmaceutical Ingredient (API) Market

• 14.1. Japan Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Salbutamol Active Pharmaceutical Ingredient (API) Market

• 15.1. Australia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Salbutamol Active Pharmaceutical Ingredient (API) Market

• 16.1. Indonesia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Salbutamol Active Pharmaceutical Ingredient (API) Market

• 17.1. South Korea Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Salbutamol Active Pharmaceutical Ingredient (API) Market

• 18.1. Taiwan Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Salbutamol Active Pharmaceutical Ingredient (API) Market

• 19.1. South East Asia Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Salbutamol Active Pharmaceutical Ingredient (API) Market

• 20.1. Western Europe Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Salbutamol Active Pharmaceutical Ingredient (API) Market

• 21.1. UK Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Salbutamol Active Pharmaceutical Ingredient (API) Market

• 22.1. Germany Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Salbutamol Active Pharmaceutical Ingredient (API) Market

• 23.1. France Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Salbutamol Active Pharmaceutical Ingredient (API) Market

• 24.1. Italy Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Salbutamol Active Pharmaceutical Ingredient (API) Market

• 25.1. Spain Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Salbutamol Active Pharmaceutical Ingredient (API) Market

• 26.1. Eastern Europe Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Salbutamol Active Pharmaceutical Ingredient (API) Market

• 27.1. Russia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Salbutamol Active Pharmaceutical Ingredient (API) Market

• 28.1. North America Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Salbutamol Active Pharmaceutical Ingredient (API) Market

• 29.1. USA Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Salbutamol Active Pharmaceutical Ingredient (API) Market

• 30.1. Canada Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Salbutamol Active Pharmaceutical Ingredient (API) Market

• 31.1. South America Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Salbutamol Active Pharmaceutical Ingredient (API) Market

• 32.1. Brazil Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Salbutamol Active Pharmaceutical Ingredient (API) Market

• 33.1. Middle East Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Salbutamol Active Pharmaceutical Ingredient (API) Market

• 34.1. Africa Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Segmentation By Formulation Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Salbutamol Active Pharmaceutical Ingredient (API) Market Regulatory and Investment Landscape

36. Salbutamol Active Pharmaceutical Ingredient (API) Market Competitive Landscape And Company Profiles

• 36.1. Salbutamol Active Pharmaceutical Ingredient (API) Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Salbutamol Active Pharmaceutical Ingredient (API) Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Salbutamol Active Pharmaceutical Ingredient (API) Market Company Profiles
  • 36.3.1. Aurobindo Pharma Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Cipla Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Lupin Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Amphastar Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Salbutamol Active Pharmaceutical Ingredient (API) Market Other Major And Innovative Companies

• Neuland Laboratories Ltd., Supriya Lifescience Ltd., Lusochimica S.p.A., Intas Pharmaceuticals Ltd., Olon S.p.A., VIVAN Life Sciences, Vamsi Labs Ltd., Aarti Pharmalabs Ltd., Chemcopia, Cerata Pharma, Hetero Labs Ltd., Granules India Ltd., MSN Laboratories Ltd., Macleods Pharmaceuticals Ltd., Zydus Lifesciences Ltd.

38. Global Salbutamol Active Pharmaceutical Ingredient (API) Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Salbutamol Active Pharmaceutical Ingredient (API) Market

40. Salbutamol Active Pharmaceutical Ingredient (API) Market High Potential Countries, Segments and Strategies

• 40.1 Salbutamol Active Pharmaceutical Ingredient (API) Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Salbutamol Active Pharmaceutical Ingredient (API) Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Salbutamol Active Pharmaceutical Ingredient (API) Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer